Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

First-line Treatment Strategies for BRAF-Mutant Metastatic Melanoma: Ipilimumab & Nivolumab

May 5th 2022

Dr Michael Atkins and Dr Evan Lipson review data from the DREAMseq trial, which evaluated nivolumab plus ipilimumab, in treatment-naïve patients with BRAFV600-mutated melanoma.

FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma

May 2nd 2022

Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians associated with the doublet, and the potential next steps for this therapy in melanoma.

Dr. Edington on the Utilization of TVEC Therapy in Melanoma

April 28th 2022

Howard D. Edington, MD, discusses the use of talimogene laherparepvec in melanoma.

Dr. Kirkwood on the Use of Ipilimumab/Nivolumab in Melanoma With Brain Metastases

April 26th 2022

John M. Kirkwood, MD, discusses the utilization of ipilimumab and nivolumab in patients with melanoma with brain metastases.

First-line and Subsequent Treatment Strategies for Unresectable/Metastatic Melanoma: A Patient Profile

April 26th 2022

Dr Michael Atkins and Dr Evan Lipson introduce and discuss a patient with unresectable stage IV metastatic melanoma.

The Current State of Metastatic Melanoma

April 26th 2022

Dr Evan Lipson provides a brief overview of metastatic melanoma including information on incidence and prognosis. He also covers the current state of biomarker testing for patients recently diagnosed with metastatic melanoma.

Dr. Edington on the Utilization of TIL Therapy in Melanoma

April 21st 2022

Howard D. Edington, MD, discusses the utilization of tumor-infiltrating lymphocyte therapy in melanoma.

Nivolumab Plus Relatlimab Aims to Become Primary Treatment Option for Advanced Melanoma

April 21st 2022

The addition of novel anti–LAG-3 antibody relatlimab-rmbw to antiPD-1 antibody nivolumab offers treatment-naïve patients with unresectable or metastatic melanoma an efficacious and tolerable immunotherapy treatment option.

Dr. Moon on the Utilization of Relatlimab Plus Nivolumab in Metastatic Melanoma

April 19th 2022

Helen Heng-Shan Moon, MD, discusses the utilization of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Tebentafusp Offers Path Forward in the Uveal Melanoma Treatment Landscape

April 19th 2022

Marlana M. Orloff, MD, overviews how pivotal efficacy and safety data of tebentafusp will improve the treatment paradigm for adult patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma.

Systemic Advances Shine, But Multidisciplinary Approaches Remain at Core of Skin Cancer Treatment

April 19th 2022

Jason Luke, MD, FACP, reviews key points from each presentation from an Institutional Perspectives in Cancer webinar on melanoma and provides perspective on the practice-changing benefits of therapies moving into earlier lines of treatment.

Dr. Edington on the Importance of Prevention Strategies in Melanoma

April 19th 2022

Howard D. Edington, MD, discusses the importance of prevention strategies in melanoma.

Dr. Tawbi on the Utilization of Relatlimab and Nivolumab in Metastatic Melanoma

April 18th 2022

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Dr. Moon on the FDA Approval of Relatlimab Plus Nivolumab in Metastatic Melanoma

April 13th 2022

Helen Heng-Shan Moon, MD, discusses the FDA approval of relatlimab plus nivolumab in patients with unresectable or metastatic melanoma.

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13th 2022

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

Dr. Edington on the Evolving Treatment Paradigm of Melanoma

April 12th 2022

Howard D. Edington, MD, discusses the evolving treatment paradigm of melanoma.

Second-Line Nivolumab Plus Ipilimumab Improves PFS in Advanced Melanoma

April 12th 2022

The combination of nivolumab and ipilimumab demonstrated a statistically significant improvement in progression-free survival vs ipilimumab alone as second-line therapy in previously treated patients with stage III unresectable or stage IV melanoma.

BO-112 Plus Pembrolizumab Generates Responses in PD-1–Resistant Advanced Melanoma

April 12th 2022

The addition of BO-112 to pembrolizumab demonstrated efficacy and safety in patients with advanced melanoma who were resistant to anti–PD-1 therapies, according to final results from the phase 2 SPOTLIGHT203 trial.

Nivolumab Plus PD-L1/IDO Peptide Vaccine Displays Impressive Efficacy in Metastatic Melanoma

April 8th 2022

Nivolumab in combination with a PD-L1/IDO peptide vaccine displayed encouraging efficacy and survival results among patients with metastatic melanoma.

RP1/Nivolumab Combo Produces Deep, Durable Responses in Melanoma and Other Skin Cancers

April 6th 2022

The combination of the oncolytic vaccine vusolimogene oderparepvec and nivolumab continued to drive encouraging responses with acceptable tolerability in patients with melanoma and other skin cancers.